Business
India
JM Financial calls Metropolis Healthcare ‘best-value diagnostic stock’, sees up to 27% upside
JM Financial has retained its Buy rating on Metropolis Healthcare with a target price of Rs 734, implying 27.2% upside. The brokerage calls it the cheapest among India’s leading listed diagnostic players, citing attractive valuations, network expansion, stronger B2C growth and improving margins as…
Continue Reading on Economic Times - Markets
This article is aggregated from Economic Times - Markets. Click below to read the full story.
Bloomberg